Trials / Recruiting
RecruitingNCT06222034
Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)
An Open-label, Multiple Dose, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Filgotinib in Children and Adolescents From 8 to Less Than 18 Years of Age With Juvenile Idiopathic Arthritis
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Alfasigma S.p.A. · Industry
- Sex
- All
- Age
- 8 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
A Study to evaluate the pharmacokinetics, safety, and tolerability in paediatric population for treating juvenile idiopathic arthritis (JIA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Filgotinib | Film-coated mini-tablets administered orally once daily |
| DRUG | Filgotinib | Commercially developed film-coated tablet administered orally once daily |
Timeline
- Start date
- 2024-05-13
- Primary completion
- 2026-03-01
- Completion
- 2026-08-01
- First posted
- 2024-01-24
- Last updated
- 2025-12-10
Locations
10 sites across 5 countries: France, Germany, Poland, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT06222034. Inclusion in this directory is not an endorsement.